Doxycycline Hydrochloride Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as the hydrochloride hemiethanolate hemihydrate solvate designated in compendial monographs as doxycycline hyclate. The material is identified by CAS 24390-14-5 and has molecular formula C₂₂H₂₄N₂O₈·HCl·0.5 C₂H₆O·0.5 H₂O and relative molecular mass 512.94 g/mol. A universal model designation does not exist for this pharmacopoeial substance; the product is controlled by the USP Doxycycline Hyclate monograph, Ph.Eur. monograph 0272, and corresponding BP/JP monographs. The API is manufactured for use as an active ingredient in immediate-release oral solid dosage forms, granules for reconstitution, and sterile injectable presentations after appropriate downstream processing. Oral and injectable grades differ principally in bioburden, bacterial endotoxin, particulate matter, and container-closure requirements, not in the chemical identity of the doxycycline hyclate solvate. The material is hygroscopic and light-sensitive; it is stored in tightly closed, light-resistant containers at controlled room temperature. Packaging is batch-specific, with fibre drums incorporating double polyethylene liners and desiccant sachets where required. The product is not a finished dosage form and is not intended for direct administration without formulation, filtration, sterilization, or compendial release testing.

What Release Specifications and Standard Methods Govern This API?

Release is performed against a pharmacopoeial profile. The following parameters are controlled on a batch basis for Ph.Eur./USP grade; injectable grade adds USP <85> and USP <71> testing. The ethanol content is not a residual solvent in the ordinary sense; it is a stoichiometric component of the solvate lattice and is controlled because loss of ethanol alters crystallinity and dissolution behaviour.

Elemental impurities are controlled under ICH Q3D and USP <232>/<233>; oral and injectable grades are assessed against separate parenteral and oral permitted daily exposures. Particle size distribution is not fixed in all pharmacopoeial monographs, but it is routinely specified by the dosage-form manufacturer using laser diffraction per USP <429> or sieve analysis per USP <786>. Published data for a universal particle-size specification is limited; the value must be derived from the intended downstream process and blend uniformity requirements.

Tablet and capsule production with doxycycline hyclate is designed around its water solubility and hygroscopicity. Aqueous wet granulation is generally avoided because the drug substance dissolves in the granulating fluid and, upon drying, can form a hard, poorly compressible matrix with increased epimerization to 4-epi-doxycycline. Direct compression and roller compaction are preferred. Where roller compaction is used, the material is blended with a dry binder and disintegrant before passing through a roller compactor fitted with vacuum deaeration; granule density and ribbon thickness are selected to achieve a Carr compressibility index below 25 as measured by USP <1174>. Content uniformity is verified by USP <905>. Capsule filling on dosator or tamping-pin machines requires control of powder flow at ambient relative humidity; if the processing suite exceeds 60% RH, the API can take up moisture and reduce flowability and assay stability. Tablets and capsules are frequently packaged in opaque PVC/PVDC/aluminium blisters with desiccant, and the bulk API is not left exposed to direct light. Granules for reconstitution require additional taste-masking and suspending-agent compatibility because doxycycline hyclate has a bitter taste and the solution pH is acidic. Compaction force, punch speed, and die-fill settings are not fixed by the API; they are established by the downstream manufacturer using formulation-specific design-of-experiments and are not part of the API release certificate. Batch-to-batch variability in particle morphology can shift the optimum compression force, so the API certificate of analysis should include particle size, bulk density, and tapped density data.

Solid-state characterization of the API is performed by X-ray powder diffraction and differential scanning calorimetry. The hyclate solvate shows a crystalline pattern that is distinct from doxycycline monohydrate; loss of ethanol and water under elevated temperature or humidity can alter crystallinity and dissolution. The manufacturer should verify the XRPD pattern against a qualified reference standard before tablet compression. Bulk density, tapped density, and derived flow indices are determined by USP <616>. For doses in the 50–100 mg range, micronization is not routinely required; however, if the drug load is reduced for pediatric or veterinary formulations, particle size control becomes critical for content uniformity. Blending with colloidal silicon dioxide and microcrystalline cellulose is common, but the exact ratio is fixed by blending studies under USP <905>.

When Injectable-Grade Doxycycline Hydrochloride Moves Through Sterile Fill-Finish

For injectable presentations, the API is dissolved in Water for Injection at pH 2.0–3.0 to maintain the protonated, water-soluble form. The solution is clarified through a 0.45 µm prefilter and sterilized by aseptic filtration through a 0.22 µm membrane; terminal steam sterilization at 121°C is generally avoided because doxycycline undergoes pH-dependent epimerization and oxidation at elevated temperature. After filtration, the solution is filled as a sterile bulk solution or lyophilized; the solid-state lyophilized cake offers greater chemical stability than an aqueous solution at room temperature. The injectable grade is tested for sterility by USP <71>, bacterial endotoxins by USP <85>, and particulate matter by USP <788>. Endotoxin limits are assigned per the finished product label and are not universally fixed in the API monograph; the manufacturer must demonstrate that the final reconstituted solution meets the limit calculated from the maximum adult dose. The acidic pH of the reconstituted injection can cause venous irritation on peripheral administration; slow infusion and dilution in a compatible infusion fluid are stipulated in approved labeling. Compounding with calcium-containing parenteral fluids should be avoided unless documented compatibility exists, because tetracycline-class antibiotics may chelate divalent cations and form precipitates. Storage of reconstituted solution at 2–8°C is limited to the in-use period defined by finished-product stability data; published data for extended in-use storage beyond approved labeling is limited.

A Direct Comparison with Doxycycline Monohydrate and Tetracycline Hydrochloride

The hydrochloride hyclate solvate differs from doxycycline monohydrate primarily in aqueous solubility and route of administration. Doxycycline monohydrate is practically insoluble in water and is used in oral suspension and solid-dose products where slower dissolution reduces local oesophageal irritation; doxycycline hyclate is freely soluble in water and is therefore suitable for injectable products and for immediate-release tablets and capsules. The two forms contain the same active moiety and have the same antibacterial mechanism of action: reversible binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA attachment. The choice between the two is a formulation decision, not a difference in antimicrobial spectrum. Compared with tetracycline hydrochloride, doxycycline has a longer elimination half-life, typically 16–22 h, allowing once-daily or twice-daily dosing, while tetracycline hydrochloride has a half-life of approximately 6–12 h. Doxycycline is eliminated to a greater extent by non-renal routes, so dose adjustment is generally unnecessary in patients with reduced renal function, whereas tetracycline accumulation can occur.

Compared with minocycline hydrochloride, doxycycline is less lipophilic and has a generally shorter half-life than minocycline; minocycline contains a dimethylamino substituent at C-7 and exhibits different tissue distribution and adverse-event profile. This distinction is relevant when selecting an API for central nervous system penetration or when balancing vestibular adverse events. Doxycycline is used in many respiratory and rickettsial indications, while minocycline is used in slow-growing mycobacterial infections and some skin and soft-tissue infections. These therapeutic differences do not alter the pharmacopoeial release requirements for doxycycline hyclate API.

The API should not be milled under high-humidity conditions or stored in unlined metal containers. Contact with strong oxidizing agents, strong acids, and divalent or trivalent cations should be avoided in dry blending; chelation with iron, calcium, magnesium, and aluminium can reduce oral bioavailability if coadministered with antacids or mineral supplements. The material is light-sensitive; prolonged exposure to direct sunlight or UV sources increases the formation of degradation products. If the manufacturing environment exceeds 60% RH, pre-drying of the processing suite or use of a dehumidified transfer isolator is recommended. These boundary conditions follow from the hygroscopic nature of the solvate and from compendial storage statements. Published data for this specific configuration is limited in the case of continuous wet granulation, so process capability studies under ICH Q1A(R2) storage conditions are required before scale-up.